Christine DeLorenzo, PhD

Dr. Christine DeLorenzo is Interim Co-Director of the Center for Healthy Aging and Professor of Psychiatry and Biomedical Engineering at Stony Brook University. Her work integrates PET and MRI imaging to identify biological markers of treatment response and guide precision medicine. 

• R01 MH137211 (2025 – 2030, NIMH) – Multi-PI with Parsey and Ritterband
  Mechanistic clinical trial evaluating the role of the metabotropic glutamate receptor subtype 5 (mGluR5) in the antidepressant mechanism of Cognitive Behavioral Therapy for Insomnia (CBT-I).
• R21 MH137546 (2024 – 2026, NIMH) – Multi-PI with Parsey
  Preliminary imaging studies evaluating the vesicular acetylcholine transporter as a treatment target in major depressive disorder (MDD).
• R01 MH125702 (2021 – 2024, NIMH) – Co-Investigator (PI: Schwartz)
  Advancing language-based analyses of social media to monitor population mental-health variation.
• R01 AA028032 (2020 – 2024, NIAAA) – Co-Investigator (PI: Schwartz)
  Large-scale data-scientific assessment of unhealthy alcohol consumption among frontline restaurant workers.
• R01 MH123093 (2020 – 2025, NIMH) – Multi-PI with Parsey
  A translational study of neuroinflammatory depression: understanding mechanism and evaluation of a novel pharmacologic intervention.
• RF1 AG064245 (2019 – 2024, NIA) – Principal Investigator
  Assessing cholinergic circuits and spatial memory loss: a translational study of Alzheimer’s disease and a model of cognitive decline.
• R01 MH114972 (2018 – 2023, NIMH) – Principal Investigator
  Role of mGluR5 in circadian rhythm misalignment and depression: implications for treatment.
• R01 MH104512 (2015 – 2020, NIMH) – Principal Investigator
  Advancing personalized antidepressant treatment using PET/MRI.
• K01 MH091354 (2011 – 2015, NIMH) – Principal Investigator
  Characterization of a new metabotropic glutamate receptor subtype 5 PET ligand.
• NARSAD Independent Investigator Grant (2016 – 2018) – Principal Investigator
  Uncovering the concurrent roles of GABA and glutamate in antidepressant treatment response.
• Dana Foundation David Mahoney Neuroimaging Grant (2015 – 2018) – Principal Investigator
  Prediction of antidepressant treatment response using MRI.
• Faculty Development Program, NYS Department of Economic Development (2019 – 2021) – Principal Investigator
  Brain imaging to improve diagnosis, monitoring, and treatment of depression.

• Dai F, Wengler K, He X, Wang J, Yang J, Parsey RV, DeLorenzo C. Lack of association between pretreatment glutamate/GABA and major depressive disorder treatment response. Transl Psychiatry. 2025 Mar 2;15(1):71. PMC11873289
• Ananth MR, Gardus JD, Huang C, Palekar N, Slifstein M, Zaborszky L, Parsey RV, Talmage DA, DeLorenzo C+, Role LW+. A central role for acetylcholine in entorhinal cortex function and dysfunction with age in humans and mice. Cell Rep. 2025 Feb 25;44(2):115249.  +co-senior author
• Lin K, Sunko D, Wang J, Yang J, Parsey RV, DeLorenzo C. Investigating the relationship between hippocampus/dentate gyrus volume and hypothalamus metabolism in participants with major depressive disorder. Sci Rep. 14(1):10622, 2024 PMC11082185
• Donnelly BM, Hsu DT, Gardus J, Wang J, Yang J, Parsey RV, DeLorenzo C. Orbitofrontal and striatal metabolism, volume, thickness and structural connectivity in relation to social anhedonia in depression: A multimodal study. Neuroimage Clin. 41:103553, 2024 PMC10777107
• Volpi T, Maccioni L, Colpo M, Debiasi G, Capotosti A, Ciceri T, Carson RE, DeLorenzo C, Hahn A, Knudsen GM, Lammertsma AA, Price JC, Sossi V, Wang G, Zanotti-Fregonara P, Bertoldo A, Veronese M. An update on the use of image-derived input functions for human PET studies: new hopes or old illusions? EJNMMI Res. 13(1):97, 2023 PMC10638226
• Abi-Dargham A, Moeller SJ, Ali F, DeLorenzo C, Domschke K, Horga G, Jutla A, Kotov R, Paulus MP, Rubio JM, Sanacora G, Veenstra-VanderWeele J, Krystal JH. Candidate biomarkers in psychiatric disorders: state of the field. World Psychiatry. 22(2):236-262, 2023 PMC10168176
• Ali FZ, Parsey RV, Lin S, Schwartz J, DeLorenzo C. Circadian rhythm biomarker from wearable device data is related to concurrent antidepressant treatment response. NPJ Digit Med. 29;6(1):81, 2023 PMC10148831
• Ali FZ, Wengler K, He X, Nguyen MH, Parsey RV, DeLorenzo C. Gradient boosting decision-tree-based algorithm with neuroimaging for personalized treatment in depression. Neurosci Inform. 2(4):100110. 2022 PMC9873411
• Narayan GA, Hill KR, Wengler K, He X, Wang J, Yang J, Parsey RV, DeLorenzo C. Does the Glutamate to GABA Ratio Correlate with Depression Severity? A Randomized, Double-Blind Clinical Trial, Molecular Psychiatry, 27(9):3833-3841, 2022 PMC9712215
• Jones JS, Goldstein SJ, Wang J, Gardus J, Yang J, Parsey RV, DeLorenzo C.  Evaluation of brain structure and metabolism in currently depressed adults with a history of childhood trauma.  Translational Psychiatry 12(1):392. 2022 PMC9482635

• 2023 - Excellence in Teaching Award, Department of Biomedical Engineering, Stony Brook University
• 2019 - Senior Research Excellence Award.  The purpose of this award is to “recognize and reward excellence among faculty in the various mission areas of the Renaissance School of Medicine.  Being considered by your colleagues as deserving of a Faculty Award is among the highest honors one member can bestow on another and a momentous personal and professional accomplishment.”
• 2019 - Excellence in Research Award, Department of Biomedical Engineering, Stony Brook University

• Member, Society of Nuclear Medicine and Molecular Imaging
• Member, American College of Neuropsychopharmacology
• Associate Editor, Frontiers in Neuropharmacology